Abstract:

Objective To study the relationship between B-type natriuretic peptide(BNP) and cardiorenal syndrome, so as to provide additional theoretical basis for clinical treatment.
Methods Totally 216 patients with acute or chronic heart failure were enrolled. Those without kidney dysfunction were enrolled into a group named simple heart failure group(113 cases) and those with kidney dysfunction were assigned into the group named cardiorenal syndrome group(103 cases). The blood concentration of BNP and N-terminal prosoma of B-type natriuretic peptide(NT-ProBNP) were determined by using fluorescence immunoassay(FIA) in patients. The 30-day mortality was determined by following-up.
Results Compared with patients of simple heart failure group, those with cardiorenal syndrome had a higher level of BNP and NT-ProBNP, 334.00(180.50~628.00)pg/mL vs 794.00(509.00~1 620.00)pg/mL(P<0.01), 22.51(13.09~35.26)ng/mL vs 32.62(21.10~61.24)ng/mL(P<0.01) separately. Compared with patients of simple heart failure group, those with cardiorenal syndrome had a higher 30-days mortality, 7.1% vs 24.3%( P<0.01).
Conclusion The decompensation of BNP may lead to the progress of cardiorenal syndrome. Patients with heart failure combined with kidney dysfunction have poor prognosis, and have a significantly increased mortality in short term.

Key words: B-type natriuretic peptide, N-terminal prosoma of B-type natriuretic peptide, cardiorenal syndrome